



Corrigendum: Five-Year Outcome After Continuous Flow LVAD With Full-Magnetic (HeartMate 3) Versus Hybrid Levitation System (HeartWare): A Propensity-Score Matched Study From an All-Comers Multicentre Registry

Alessandra Francica^{1*}, Antonio Loforte^{2,3}, Matteo Attisani³, Massimo Maiani⁴, Attilio Iacovoni⁵, Teodora Nisi⁶, Marina Comisso⁷, Amedeo Terzi⁵, Michele De Bonis⁶, Igor Vendramin⁴, Massimo Boffini³, Francesco Musumeci⁷, Giovanni Battista Luciani¹, Mauro Rinaldi³, Davide Pacini² and Francesco Onorati¹

¹Division of Cardiac Surgery, University Hospital of Verona, Verona, Italy, ²Division of Cardiac Surgery, S. Orsola University Hospital, IRCCS Bologna, Bologna, Italy, ³City of Health and Science Hospital, Cardiac Surgery University Unit, University of Turin, Turin, Italy, ⁴Division of Cardiac Surgery, Ospedale S. Maria della Misericordia, Udine, Italy, ⁵Division of Cardiac Surgery, Papa Giovanni XXII Hospital of Bergamo, Bergamo, Italy, ⁶Division of Cardiac Surgery, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy, ⁷Division of Cardiac Surgery, San Camillo Forlanini Hospital, Rome, Italy

Keywords: continuous-flow LVAD, HeartMate3, HeartWare, full-magnetic levitation pump, hybrid levitation system pump

OPEN ACCESS

*Correspondence:

Alessandra Francica alessandrafrancica@yahoo.it

Received: 21 September 2023 Accepted: 25 September 2023 Published: 09 October 2023

Citation:

Francica A, Loforte A, Attisani M,
Maiani M, Iacovoni A, Nisi T,
Comisso M, Terzi A, De Bonis M,
Vendramin I, Boffini M, Musumeci F,
Luciani GB, Rinaldi M, Pacini D and
Onorati F (2023) Corrigendum: FiveYear Outcome After Continuous Flow
LVAD With Full-Magnetic (HeartMate
3) Versus Hybrid Levitation System
(HeartWare): A Propensity-Score
Matched Study From an All-Comers
Multicentre Registry.
Transpl Int 36:12088.
doi: 10.3389/ti.2023.12088

A Corrigendum on

Five-Year Outcome After Continuous Flow LVAD With Full-Magnetic (HeartMate 3) Versus Hybrid Levitation System (HeartWare): A Propensity-Score Matched Study From an All-Comers Multicentre Registry

by Francica A, Loforte A, Attisani M, Maiani M, Iacovoni A, Nisi T, Comisso M, Terzi A, De Bonis M, Vendramin I, Boffini M, Musumeci F, Luciani GB, Rinaldi M, Pacini D and Onorati F (2023). Transpl Int. 36:11675. doi: 10.3389/ti.2023.11675

In the original article, there was a mistake in the **Graphical Abstract** as published. The propensity-score matching survival was incorrectly given as "64.1% vs. 81.3% (p .02)". The correct values are "64.1% for HM3 vs. 41.7% in HVAD (p 0.02)". The Kaplan-Meier curve is correct, it was just a transcription error.

The corrected **Graphical Abstract** appears below.


1

The same mistake was present in the text body. A correction has been made to the **Abstract** and to the **Results** section:

Abstract: "The propensity-score matching analysis (130 pairs of HVAD vs. HM3) confirmed a significantly lower 5 years survival (41.7% vs. 64.1%; *p* 0.02)..."

Results, *Propensity Matched Population*: "HVAD patients confirmed a significantly lower 5 years survival (64.1% vs. 41.7%; *p* 0.02) (Figure 2B)..."

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.



Copyright © 2023 Francica, Loforte, Attisani, Maiani, Iacovoni, Nisi, Comisso, Terzi, De Bonis, Vendramin, Boffini, Musumeci, Luciani, Rinaldi, Pacini and Onorati. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or

reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.